Journal of Clinical and Cellular Immunology
Open Access

ISSN: 2155-9899

Journal of Clinical and Cellular Immunology : Citations & Metrics Report

Articles published in Journal of Clinical and Cellular Immunology have been cited by esteemed scholars and scientists all around the world. Journal of Clinical and Cellular Immunology has got h-index 42, which means every article in Journal of Clinical and Cellular Immunology has got 42 average citations.

Following are the list of articles that have cited the articles published in Journal of Clinical and Cellular Immunology.

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Total published articles	30	31	30	59	28	11	35	56	95	105	101	105	64	15	3
Research, Review articles and Editorials	2	13	8	23	18	8	25	35	54	86	79	35	23	14	3
Research communications, Review communications, Editorial communications, Case reports and Commentary	20	18	22	22	10	3	10	21	39	6	9	7	1	1	0
Conference proceedings	0	16	15	6	0	98	178	206	171	160	195	156	74	0	0
Citations received as per Google Scholar, other indexing platforms and portals	653	826	931	1079	1018	971	871	851	753	550	276	145	43	40	0

Journal total citations count	8361
Journal impact factor	24.12
Journal 5 years impact factor	31.14
Journal cite score	30.45
Journal h-index	42
Journal h-index since 2019	32

Important citations (1511)

soelberg sorensen p (2016) safety concerns and risk management of multiple sclerosis therapies acta neurologica scandinavica. View at Publisher View at Google Scholar
Nicklen j. human herpesvirus 6, varicella-zoster virus and oligoclonal bands in demyelinating diseases of the central nervous system. View at Publisher View at Google Scholar
Ziemssen t, de stefano n, sormani mp, van wijmeersch b, wiendl h, kieseier bc. multiple sclerosis and related disorders. View at Publisher View at Google Scholar
Comi g, radaelli m, sÃ¸rensen ps (2016). evolving concepts in the treatment of relapsing multiple sclerosis the lancet. View at Publisher View at Google Scholar
Freedman ms, rush ca (2016) severe, highly active, or aggressive multiple sclerosis. continuum: lifelong learning in neurology multiple sclerosis and other demyelinating diseases 22:761-84. View at Publisher View at Google Scholar
Ziemssen t, gass a, wuerfel j, bayas a, tackenberg b, et al. (2016). design of trust, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab bmc neurology 16:98. View at Publisher View at Google Scholar
Singer ba (2016). parenteral treatment of multiple sclerosis: the advent of monoclonal antibodies. inseminars in neurology thieme medical publishers 36: 140-147 View at Publisher View at Google Scholar
Willis md, robertson np (2016). alemtuzumab for multiple sclerosis. current neurology and neuroscience reports 16:84. View at Publisher View at Google Scholar
Gross rh, krieger s (2015) alemtuzumab in multiple sclerosis: an update. neurodegenerative disease management 5:225-32. View at Publisher View at Google Scholar
Alten r, bingham co, cohen sb, curtis jr, kelly s, et al. (2016) antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. bmc musculoskeletal disorders 17: 231. View at Publisher View at Google Scholar
Eibl mm, wolf hm. vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. View at Publisher View at Google Scholar
Ziemssen t, engelmann u, jahn s, leptich a, kern r, et al.(2016) rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on alemtuzumab in multiple sclerosis patients in germany (treat-ms). bmc neurology 16:109. View at Publisher View at Google Scholar
Parmley s. downstream without a net. View at Publisher View at Google Scholar
Wizeman jw, nicholas ap, ishigami a, mohan r (2016) citrullination of glial intermediate filaments is an early response in retinal injury. molecular vision 22: 1137. View at Publisher View at Google Scholar
KaÅafut j, pÅonka m (2014) new discoveries in the field of rheumatoid. biotechnology progressâ€“the polish studentsâ€™ scientific interests 2014:139. View at Publisher View at Google Scholar
Hasler p, giaglis s, hahn s (2016) neutrophil extracellular traps in health and disease. swiss med wkly 146: w14352. View at Publisher View at Google Scholar
Hassoun l, eisele j, thomas k, ziemssen t (2016) hands on alemtuzumab-experience from clinical practice: whom and how to treat. multiple sclerosis and demyelinating disorders 1:10. View at Publisher View at Google Scholar
Chirivi rg, van rosmalen jw, jenniskens gj, pruijn gj, raats jm (2013) citrullination: a target for disease intervention in multiple sclerosis and other inflammatory diseases. j clin cell immunol 4: 4172. View at Publisher View at Google Scholar
Corsiero e, bombardieri m, carlotti e, pratesi f, robinson w, et al. (2015) single cell cloning and recombinant monoclonal antibodies generation from ra synovial b cells reveal frequent targeting of citrullinated histones of nets. annals of the rheumatic diseases. View at Publisher View at Google Scholar
Behrendt r, white p, offer j (2016) advances in fmoc solidâ€phase peptide synthesis. journal of peptide science 22: 4-27. View at Publisher View at Google Scholar
Prev 1 2 ... 35 36 37 38 39 40 41 42 43 44 45 ... 75 76 Next »

Top